National Institutes of Health’s (NIH) National Cancer Institute (NCI) began accepting applications for Phase IIB Bridge Awards to accelerate the development of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics toward commercialization, on October 6, 2012. There are two application due dates for this Funding Opportunity Announcement: November 6, 2012 and March 6, 2013.
As indicated in the RFA which was posted on August 17th, and is available at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-023.html:
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded by NIH SBIR Phase II awards. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.
Click on the following LINK for more detailed information on this opportunity.
